% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Kuo:276245,
author = {P. H. Kuo and D. C. Yoo and R. Avery and M. Seltzer and J.
Calais and J. Nagarajah and W. A. Weber and W. P.
Fendler$^*$ and M. S. Hofman and B. J. Krause and M.
Brackman and E. Kpamegan and S. Ghebremariam and T. Benson
and A. M. Catafau and A. T. Kendi},
title = {{A} {VISION} {S}ubstudy of {R}eader {A}greement on
68{G}a-{PSMA}-11 {PET}/{CT} {S}can {I}nterpretation to
{D}etermine {P}atient {E}ligibility for 177{L}u-{PSMA}-617
{R}adioligand {T}herapy.},
journal = {Journal of nuclear medicine},
volume = {64},
number = {8},
issn = {0097-9058},
address = {New York, NY},
publisher = {Soc.},
reportid = {DKFZ-2023-01047},
pages = {1259-1265},
year = {2023},
note = {2023 Aug;64(8):1259-1265},
abstract = {68Ga-gozetotide (68Ga-PSMA-11) is used to identify
prostate-specific membrane antigen (PSMA)-positive tumors on
PET scans. In the VISION study, 68Ga-PSMA-11 was used to
determine the eligibility of patients with metastatic
castration-resistant prostate cancer for treatment with
177Lu-vipivotide tetraxetan (177Lu-PSMA-617), based on
predefined read criteria. This substudy aimed to investigate
the interreader variability and intrareader reproducibility
of visual assessments of 68Ga-PSMA-11 PET/CT scans using the
VISION read criteria and evaluate the agreement between read
results for this and the VISION study. Methods: In VISION,
68Ga-PSMA-11 PET/CT scans were centrally read as inclusion
cases if they had at least 1 PSMA-positive lesion and no
PSMA-negative lesions that fulfilled the exclusion criteria.
In this substudy, 125 PET/CT scans (75 inclusion and 50
exclusion cases) were randomly selected from VISION and
retrospectively assessed by 3 independent central readers. A
random subset of 20 cases (12 inclusion and 8 exclusion
cases) was recoded for assessment of intrareader
reproducibility. Classification of cases as inclusion or
exclusion cases was based on the VISION read criteria.
Overall interreader variability was assessed by Fleiss
κ-statistics, and pairwise variability and intrareader
reproducibility were assessed by Cohen κ-statistics.
Results: For interreader variability, the readers agreed on
$77\%$ of cases (overall average agreement rate, 0.85;
Fleiss κ, 0.60 $[95\%$ CI, 0.50-0.70]). The pairwise
agreement rate was 0.82, 0.88, and 0.84, and the
corresponding Cohen κ was 0.54 $(95\%$ CI, 0.38-0.71), 0.67
$(95\%$ CI, 0.52-0.83), and 0.59 $(95\%$ CI, 0.43-0.75),
respectively. For intrareader reproducibility, the agreement
rate was 0.90, 0.90, and 0.95, and the corresponding Cohen
κ was 0.78 $(95\%$ CI, 0.49-0.99), 0.76 $(95\%$ CI,
0.46-0.99), and 0.89 $(95\%$ CI, 0.67-0.99), respectively.
The number of actual VISION inclusion cases out of the total
number of cases scored as inclusion in this substudy was 71
of 93 (agreement rate, 0.76; $95\%$ CI, 0.66-0.85) for
reader 1, 70 of 88 (0.80; 0.70-0.87) for reader 2, and 73 of
96 (0.76; 0.66-0.84) for reader 3. All readers agreed on 66
of 75 VISION inclusion cases. Conclusion:
Moderate-to-substantial interreader agreement and
substantial-to-almost perfect intrareader reproducibility
for 68Ga-PSMA-11 PET/CT scan assessment using the VISION
read criteria were observed. The read rules applied in
VISION can be readily learned and demonstrate good
reproducibility.},
keywords = {PET/CT (Other) / PSMA (Other) / prostate cancer (Other)},
cin = {ED01},
ddc = {610},
cid = {I:(DE-He78)ED01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37230533},
doi = {10.2967/jnumed.122.265077},
url = {https://inrepo02.dkfz.de/record/276245},
}